Current Report Filing (8-k)
01 November 2022 - 11:03PM
Edgar (US Regulatory)
0001633070FALSE00016330702022-11-012022-11-01
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_____________________
FORM 8-K
_____________________
CURRENT REPORT
Pursuant to Section 13 OR 15(d)
of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
November 1, 2022
_____________________
AXCELLA HEALTH INC.
(Exact name of registrant as specified in its charter)
________________________
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Delaware |
|
001-38901 |
|
26-3321056 |
(State or other jurisdiction
of incorporation) |
|
(Commission
File Number) |
|
(IRS Employer
Identification No.) |
|
|
|
|
|
|
|
|
|
840 Memorial Drive
Cambridge, Massachusetts
|
02139 |
(Address of principal executive offices) |
(Zip Code) |
Registrant's telephone number, including area code:
(857) 320-2200
Not Applicable
(Former name or former address, if changed since last
report)
________________________
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions ( see General
Instruction A.2. below):
|
|
|
|
|
|
|
|
|
☐ |
Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425) |
|
|
|
|
|
|
|
|
|
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12) |
|
|
|
|
|
|
|
|
|
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b)) |
|
|
|
|
|
|
|
|
|
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
|
|
|
|
|
|
|
|
|
|
Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered |
Common Stock, $0.001 Par Value |
AXLA |
Nasdaq Global Market |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company x
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange
Act.
¨
Item 2.02. Results
of Operations and Financial Condition.
On November 1, 2022, Axcella Health Inc., doing business as
“Axcella Therapeutics,” announced its financial results for the
second quarter ended September 30, 2022. The full text of the
press release issued in connection with the announcement is
furnished as Exhibit 99.1 to this Current Report on Form
8-K.
The information in this Form 8-K (including Exhibit 99.1) shall not
be deemed “filed” for purposes of Section 18 of the Securities
Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise
subject to the liabilities of that section, nor shall it be deemed
incorporated by reference in any filing under the Securities Act of
1933, as amended, or the Exchange Act, except as expressly set
forth by specific reference in such a filing.
Item 9.01. Financial
Statements and Exhibits.
(d) Exhibits:
|
|
|
|
|
|
|
|
|
|
|
|
|
Exhibit
No. |
|
Description |
|
|
99.1 |
|
|
104 |
|
Cover Page Interactive Data File (embedded within the Inline XBRL
document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned hereunto duly
authorized.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
AXCELLA HEALTH INC. |
|
|
|
|
Date: November 1, 2022 |
|
|
|
By: |
|
/s/ William R. Hinshaw, Jr. |
|
|
|
|
|
|
William R. Hinshaw, Jr. |
|
|
|
|
|
|
President, Chief Executive Officer and Director |
Axcella Health (NASDAQ:AXLA)
Historical Stock Chart
From Feb 2023 to Mar 2023
Axcella Health (NASDAQ:AXLA)
Historical Stock Chart
From Mar 2022 to Mar 2023